EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Liposomal bupivacaine provides superior pain control compared to bupivacaine with adjuvants in interscalene block for total shoulder replacement: a prospective double-blinded, randomized controlled trial

Kevin J Finkel, Aseel Walker, Carla L Maffeo-Mitchell, Carl Nissen, Pranjali Kainkaryam, Jennifer Sposito, Emily Shearier, Edmund T Takata, Ilene Staff, Theodore Blaine, Durgesh Nagarkatti

Journal of Shoulder and Elbow Surgery · 2024

DOI: 10.1016/j.jse.2023.12.014 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Shoulder and Elbow Surgery, 2024. Verfasst von Kevin J Finkel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Integrated Anesthesia Associates, Hartford Hospital, Hartford, CT, USA. Electronic address: kevin.finkel@iaapartners.com. Hauptthemen laut MEDLINE: Bupivacaine, Arthroplasty, Replacement, Shoulder, Postoperative Pain, Anesthetics, Local. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Optimal pain control methods after total shoulder arthroplasty (TSA) achieve reduced opioid consumption, shortened hospital stay, and improved patient satisfaction in addition to adequate analgesia. Interscalene brachial plexus block is the gold standard for TSA, yet it typically does not provide pain relief lasting beyond 24 hours. Liposomal bupivacaine (LB) purportedly provides prolonged analgesia, yet it has been minimally explored for interscalene block, and it is significantly more expensive than standard bupivacaine. METHODS: This is a prospective, 2-arm, double-blinded randomized controlled trial. Subjects presenting for anatomic or reverse TSA were randomized in a 1:1 ratio to receive interscalene brachial plexus block with either LB plus bupivacaine (LBB group) or bupivacaine plus dexamethasone and epinephrine (BDE group). The primary outcome was 120-hour postoperative opioid consumption. Secondary outcomes were pain scores up to 96 hours postoperatively, pain control satisfaction, complications, level of distress from block numbness, and hospital stay. RESULTS: Ninety patients, 45 per group, were included in the intention-to-treat analysis and randomized. Because of withdrawal of consent and loss to follow-up, 40 in each group completed enrollment through postoperative day 60. Total 120-hour postoperative opioid consumption was similar between groups (P = .127), with no differences within 24- or 48-hour time intervals. Postoperative pain scores at 24-48 hours, 48-72 hours, 72-96 hours, and day 60 were significantly lower for the LBB group. DISCUSSION: LB interscalene brachial plexus block before total shoulder arthroplasty did not reduce 120-hour postoperative opioid consumption but significantly reduced postoperative pain between 24 and 96 hours and at postoperative day 60.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BupivacaineArthroplasty, Replacement, ShoulderPostoperative PainAnesthetics, LocalLiposomesHumansDouble-Blind MethodMaleFemaleMiddle AgedProspective StudiesAgedBrachial Plexus BlockPain MeasurementEpinephrineDexamethasonePain Management

Stichwörter der Autor:innen

Liposomal bupivacaineinterscalene nerve blocklocal anesthesiaperioperative pain managementpostoperative analgesiaregional anesthesia

Substanzen

BupivacaineAnesthetics, LocalLiposomesEpinephrineDexamethasone

Autor:innen und Institutionen

  • Integrated Anesthesia Associates, Hartford Hospital, Hartford, CT, USA. Electronic address: kevin.finkel@iaapartners.com.
  • Integrated Anesthesia Associates, Hartford Hospital, Hartford, CT, USA.
  • Bone & Joint Institute, Hartford Hospital, Hartford, CT, USA.
  • Research Administration, Hartford Hospital, Hartford, CT, USA.
  • Hospital for Special Surgery, New York, NY, USA.

Zitieren

APA

Finkel, K. J., Walker, A., Maffeo-Mitchell, C. L., Nissen, C., Kainkaryam, P., Sposito, J., Shearier, E., Takata, E. T., Staff, I., Blaine, T., & Nagarkatti, D. (2024). Liposomal bupivacaine provides superior pain control compared to bupivacaine with adjuvants in interscalene block for total shoulder replacement: a prospective double-blinded, randomized controlled trial. Journal of Shoulder and Elbow Surgery. https://doi.org/10.1016/j.jse.2023.12.014

Vancouver

Finkel KJ, Walker A, Maffeo-Mitchell CL, Nissen C, Kainkaryam P, Sposito J, et al. Liposomal bupivacaine provides superior pain control compared to bupivacaine with adjuvants in interscalene block for total shoulder replacement: a prospective double-blinded, randomized controlled trial. Journal of Shoulder and Elbow Surgery. 2024. doi:10.1016/j.jse.2023.12.014

BibTeX
@article{Finkel2024,
  author = {Finkel, Kevin J and Walker, Aseel and Maffeo-Mitchell, Carla L and Nissen, Carl and Kainkaryam, Pranjali and Sposito, Jennifer and Shearier, Emily and Takata, Edmund T and Staff, Ilene and Blaine, Theodore and Nagarkatti, Durgesh},
  title = {Liposomal bupivacaine provides superior pain control compared to bupivacaine with adjuvants in interscalene block for total shoulder replacement: a prospective double-blinded, randomized controlled trial},
  journal = {Journal of Shoulder and Elbow Surgery},
  year = {2024},
  doi = {10.1016/j.jse.2023.12.014}
}
Kostenlos starten →